Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Anthony L TraboulseeDavid K B LiMark CascioneJuanzhi FangFernando DangondAaron MillerPublished in: BMC neurology (2018)
Clinical, radiological, and NEDA outcomes at Year 1 were consistent with Year 2 results. Treatment efficacy was consistent in pre-specified patient subgroups.